Functional and Therapeutic Relevance of CD56(NCAM) Expression in Multiple Myeloma

被引：0
|
作者：
Gattenlohner, S.
Mottok, A.
Stuhmer, T.
Bargou, R.
Einsele, H.
Muller-Hermelink, H-K
机构：
[1] Med Univ Graz, Inst Pathol, Graz, Austria
[2] Univ Wurzburg, Inst Pathol, D-97070 Wurzburg, Germany
来源：
MODERN PATHOLOGY | 2011年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1263
引用
收藏
页码：297A / 297A
页数：1
相关论文
共 50 条
  • [1] Functional and Therapeutic Relevance of CD56(NCAM) Expression in Multiple Myeloma
    Gattenlohner, S.
    Mottok, A.
    Stuhmer, T.
    Bargou, R.
    Einsele, H.
    Muller-Hermelink, H-K
    LABORATORY INVESTIGATION, 2011, 91 : 297A - 297A
  • [2] Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma
    Kraj, Maria
    Sokolowska, Urszula
    Kopec-Szlezak, Joanna
    Poglod, Ryszard
    Kruk, Barbara
    Wozniak, Jolanta
    Szpila, Tomasz
    LEUKEMIA & LYMPHOMA, 2008, 49 (02) : 298 - 305
  • [3] THE ROLE OF CD56 EXPRESSION IN SMOLDERING MULTIPLE MYELOMA
    Notarfranchi, L.
    Storti, P.
    Vescovini, R.
    Segreto, R.
    Bonomini, S.
    Sammarelli, G.
    Todaro, G.
    Raimondi, V.
    Burroughs-Garcia, J.
    Toscani, D.
    Dalla Palma, A. B.
    Giuliani, N.
    HAEMATOLOGICA, 2022, 107 : 44 - 44
  • [4] The impact of CD56 expression in smoldering Multiple Myeloma
    Notarfranchi, Laura
    Vescovini, Rosanna
    Segreto, Roberta
    Bonomini, Sabrina
    Storti, Paola
    Marchica, Valentina
    Sammarelli, Gabriella
    Todaro, Giannalisa
    Soressi, Naomi
    De Giovanni, Dario
    Burroughs-Garcia, Jessica
    Toscani, Denise
    Palma, Anna Benedetta Dalla
    Giuliani, Nicola
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S111 - S111
  • [5] Redefining CD56 as a Biomarker and Therapeutic Target in Multiple Myeloma
    Cottini, Francesca
    Rodriguez, Jose
    Hughes, Tiffany
    Sharma, Nidhi
    Guo, Ling
    Lozanski, Gerard
    Liu, Bei
    Cocucci, Emanuele
    Yang, Yiping
    Benson, Don
    MOLECULAR CANCER RESEARCH, 2022, 20 (07) : 1083 - 1095
  • [6] CD56 and EMA immunoexpressions in multiple myeloma: Any prognostic relevance?
    Dirilenoglu, F.
    Aydin, F.
    Kaya, E.
    Kalender, M. E.
    Ozdemirkiran, F.
    Kucukzeybek, B.
    Calli, A. O.
    VIRCHOWS ARCHIV, 2015, 467 : S201 - S201
  • [7] Soluble CD56 (NCAM): A new differential-diagnostic and prognostic marker in multiple myeloma
    Kaiser, U
    Oldenburg, M
    Jaques, G
    Auerbach, B
    Havemann, K
    ANNALS OF HEMATOLOGY, 1996, 73 (03) : 121 - 126
  • [8] CD56 for Multiple Myeloma: Lack of CD56 May Be Associated with Worse Prognosis
    Miyazaki, Kanji
    Suzuki, Kenshi
    ACTA HAEMATOLOGICA, 2018, 140 (01) : 40 - 41
  • [9] CD56 (NCAM) expression in ameloblastomas and other odontogenic lesions
    Cairns, Lindsey
    Naidu, Aparna
    Robinson, Conrad Max
    Sloan, Philip
    Wright, John M.
    Hunter, Keith D.
    HISTOPATHOLOGY, 2010, 57 (04) : 544 - 548
  • [10] Prognostic Relevance of Concordant Expression CD69 and CD56 in Response to Bortezomib Combination Therapy in Multiple Myeloma Patients
    ElMenshawy, Nadia
    Farag, Nora A.
    Atia, Doaa M.
    Abousamra, Nashwa
    Shahin, Doaa
    Fawzi, Eman
    Ghazi, Hayam
    El-Kott, Attalla F.
    Eissa, Mohamed
    CANCER INVESTIGATION, 2021, 39 (09) : 777 - 782
12345